`
`Page 1 of 4
`
`8-K 1 form8-k.htm IMMUNOGEN, INC. FORM 8-K
`UNITED STATES
`SECURITIES AND EXCHANGE COMMISSION
`
`Washington, D.C. 20549
`
`FORM 8-K
`
`CURRENT REPORT
`
`PURSUANT TO SECTION 13 OR 15(d)
`OF THE SECURITIES EXCHANGE ACT OF 1934
`
`Date of Report (Date of earliest event reported): January 25, 2006
`
`ImmunoGen, Inc.
`
`(Exact name of registrant as specified in its charter)
`
`Massachusetts
`(State or other jurisdiction of incorporation)
`
`0-17999
`(Commission File Number)
`
`04-2726691
`(IRS Employer Identification No.)
`
`128 Sidney Street, Cambridge, MA 02139
`(Address of principal executive offices) (Zip Code)
`
`Registrant's telephone number, including area code: (617) 995-2500
`
`Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the
`registrant under any of the following provisions (see General Instruction A.2. below):
`
`(cid:134)
`
`(cid:134)
`
`(cid:134)
`(17 CFR 240.14d-2(b))
`
`(cid:134)
`(17 CFR 240.13e-4(c))
`
`Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
`
`Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
`
`Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
`
`Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
`
`https://www.sec.gov/Archives/edgar/data/855654/000085565406000002/form8-k.htm
`
`9/30/2016
`
`
`
`JANSSEN EXHIBIT 2084
`Mylan v. Janssen IPR2016-01332
`
`
`
`ImmunoGen, Inc. form 8-K
`
`Page 2 of 4
`
`ITEM 8.01 - OTHER EVENTS
`
`On January 25, 2006, Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) notified ImmunoGen, Inc. (Nasdaq:
`IMGN) that as part of its ongoing portfolio management process and based on the evaluation of recent clinical data in the
`context of other opportunities in its pipeline, Millennium had decided not to continue the development of its MLN2704
`compound. MLN2704 consists of a Millennium antibody to the Prostate-Specific Membrane Antigen (PSMA) and
`ImmunoGen’s DM1 and was in development by Millennium under a 2001 agreement that gave Millennium rights to use
`ImmunoGen’s maytansinoid Tumor-Activated Prodrug (TAP) technology with antibodies targeting PSMA. On January
`26, 2006, Millennium publicly disclosed that it had discontinued development of MLN2704 and that it was in the process
`of evaluating whether to continue development of this antibody conjugated with other cell-killing agents including other
`maytansanoids. Millennium retains its right to use ImmunoGen’s maytansinoid TAP technology with antibodies targeting
`PSMA.
`
`2
`
`https://www.sec.gov/Archives/edgar/data/855654/000085565406000002/form8-k.htm
`
`9/30/2016
`
`
`
`ImmunoGen, Inc. form 8-K
`
`Page 3 of 4
`
`SIGNATURES
`
`Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be
`signed on its behalf by the undersigned hereunto duly authorized.
`
`Date: January 26, 2006
`
`ImmunoGen, Inc.
`(Registrant)
`
`/s/ Karleen M. Oberton
`
`Karleen M. Oberton
`Senior Corporate Controller
`(Principal Accounting Officer)
`
`3
`
`https://www.sec.gov/Archives/edgar/data/855654/000085565406000002/form8-k.htm
`
`9/30/2016
`
`
`
`ImmunoGen, Inc. form 8-K
`
`Page 4 of 4
`
`https://www.sec.gov/Archives/edgar/data/855654/000085565406000002/form8-k.htm
`
`9/30/2016
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
